Jul 22, 2021 | Press release
Södertälje, Sweden, 22 July 2021 – Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, today announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the...
Jul 22, 2021 | Press release
Södertälje, 22 juli 2021 – Anocca AB, ett världsledande svenskt bioteknikbolag för utveckling av T-cellsbehandlingar mot cancer, autoimmuna sjukdomar och virusinfektioner, meddelade idag att bolaget har stängt en serie B-finanseringsrunda på 400 miljoner kronor (47...
Jul 22, 2021 | Anocca in the news
Originally published in Endpoints News. Södertälje, Sweden, the historic home to the Astra half of AstraZeneca, may seem an unlikely place for cutting-edge R&D on T cell receptors and cell therapies. And Reagan Jarvis — a transplant from New Zealand who had...
Aug 6, 2020 | Uncategorized
Anocca AB General enquires info@anocca.com Business Development & Partnering bd@anocca.com Science & Technology sci@anocca.com Visit us on LinkedIn
Aug 20, 2018 | Uncategorized
Anocca AB Forskargatan 20C151 36 Södertälje, Sweden+46 (0)8 410 807 50 info@anocca.com Show on map Direct Contact Business Development & Partneringbd@anocca.com Science & Technologysci@anocca.com Visit us on LinkedIn Copyright © 2020 Anocca ABRegistration...
We use cookies to ensure that we give you the best experience on our website.